The antibody response after pneumococcal vaccines and their effectiveness towards invasive pneumococcal illness (IPD) in sufferers with interleukin-1 receptor-associated kinase 4 (IRAK4) deficiency haven’t been
The antibody response after pneumococcal vaccines and their effectiveness towards invasive pneumococcal illness (IPD) in sufferers with interleukin-1 receptor-associated kinase 4 (IRAK4) deficiency haven’t been